Cover Image
市場調查報告書

膽管癌:開發平台分析

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 237881
出版日期 內容資訊 英文 504 Pages
訂單完成後即時交付
價格
Back to Top
膽管癌:開發平台分析 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 504 Pages
簡介

膽管癌的症狀有腹部的不適感、食欲不振、發燒、體重減輕。這個疾病的代表性治療法有化療及放射線治療等。

本報告提供全球膽管癌治療藥的開發中產品概要,提供您目前開發平台狀況和最新趨勢,後期階段及中止的計劃等資訊,還有主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

膽管癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

膽管癌:企業開發中的治療藥

膽管癌:大學/機關研究中的治療藥

膽管癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

膽管癌:企業開發中的產品

膽管癌:大學/機關研究中的產品

膽管癌的治療藥的開發企業

  • 4SC AG
  • Adgero Biopharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Ariad Pharmaceuticals, Inc.
  • ArQule, Inc.
  • Array BioPharma Inc.
  • Arrien Pharmaceuticals, LLC
  • Aslan Pharmaceuticals Pte. Ltd.
  • Bavarian Nordic A/S
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CellAct Pharma GmbH
  • Cellceutix Corporation
  • Cellular Biomedicine Group, Inc.
  • Concordia Healthcare Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Delcath Systems, Inc.
  • Eisai
  • Eli Lilly and Company
  • Exelixis, Inc. 其他

膽管癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • vandetanib
  • AP-5346
  • cabozantinib s-malate
  • elpamotide
  • exatecan mesylate
  • LY-2801653
  • NUC-1031
  • AG-120
  • Im-01
  • PAN-622
  • ARN-5032
  • JP-1584

膽管癌:最近的開發平台趨勢

膽管癌:暫停中的計劃

膽管癌:開發中止的產品

膽管癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8167IDB

Summary

Global Markets Direct's, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
  • The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
  • The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Bile Duct Cancer (Cholangiocarcinoma) Overview
  • Therapeutics Development
  • Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies
  • Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance
  • Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies
  • Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes
  • Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
  • Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
  • Drug Profiles
  • Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
  • Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
  • Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2016
  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corporation, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corporation, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co., Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune, LLC, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co., Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Plexxikon Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2016
  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top